{"id":44189,"date":"2025-10-23T19:32:40","date_gmt":"2025-10-23T11:32:40","guid":{"rendered":"https:\/\/flcube.com\/?p=44189"},"modified":"2025-10-23T19:32:41","modified_gmt":"2025-10-23T11:32:41","slug":"roche-reports-7-yoy-revenue-growth-through-q3-2025-raises-full%e2%80%91year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44189","title":{"rendered":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance"},"content":{"rendered":"\n<p><strong>Roche (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>)<\/strong> announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached <strong>CHF\u202f45.86\u202fbillion<\/strong> (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to <strong>CHF\u202f35.56\u202fbillion<\/strong> (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching <strong>CHF\u202f10.3\u202fbillion<\/strong> (\u2248\u202fUSD\u202f12.9\u202fbillion).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1\u2011Q3\u202f2025<\/th><th>YoY %<\/th><\/tr><\/thead><tbody><tr><td><strong>Group Revenue<\/strong><\/td><td>CHF\u202f45.86\u202fbn<\/td><td>+7\u202f%<\/td><\/tr><tr><td><strong>Pharma<\/strong><\/td><td>CHF\u202f35.56\u202fbn<\/td><td>+9\u202f%<\/td><\/tr><tr><td><strong>Diagnostics<\/strong><\/td><td>CHF\u202f10.3\u202fbn<\/td><td>+1\u202f%<\/td><\/tr><tr><td><strong>Full\u2011Year Guidance<\/strong><\/td><td>Mid\u2011single\u2011digit sales growth<\/td><td>Unchanged<\/td><\/tr><tr><td><strong>Core EPS<\/strong><\/td><td>High single\u2011digit to low double\u2011digit<\/td><td>Up from prior high\u2011single\u2011digit range<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-diagnostics-china-drag-continues\"><strong>Diagnostics \u2013 China Drag Continues<\/strong><\/h3>\n\n\n\n<p>Pricing controls in China have heavily weighed on the Diagnostics arm, pushing Asia\u2011Pacific sales down <strong>\u201115\u202f% YoY<\/strong>. In contrast, other regions delivered robust growth:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EMEA<\/strong>: +6\u202f%<\/li>\n\n\n\n<li><strong>North America<\/strong>: +7\u202f%<\/li>\n\n\n\n<li><strong>Latin America<\/strong>: +14\u202f%<\/li>\n<\/ul>\n\n\n\n<p>The 1\u202f% global rise in Diagnostics sales is largely attributable to North American and Latin American gains offsetting the China slowdown.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceuticals-solid-global-expansion\"><strong>Pharmaceuticals \u2013 Solid Global Expansion<\/strong><\/h3>\n\n\n\n<p>Roche\u2019s Pharma division benefited from a diversified portfolio and strong performance across all geographies:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Sales (CHF\u202fm)<\/th><th>YoY %<\/th><\/tr><\/thead><tbody><tr><td>United States<\/td><td>18,798<\/td><td>+8\u202f%<\/td><\/tr><tr><td>Europe<\/td><td>6,818<\/td><td>+5\u202f%<\/td><\/tr><tr><td>Japan<\/td><td>2,139<\/td><td>+5\u202f%<\/td><\/tr><tr><td>International<\/td><td>7,800<\/td><td>+13\u202f%<\/td><\/tr><tr><td><strong>Global<\/strong><\/td><td>35,555<\/td><td>+9\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Growth Drivers<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phesgo<\/strong> (breast\u2011cancer combination)<\/li>\n\n\n\n<li><strong>Vabysmo<\/strong> (ophthalmology)<\/li>\n\n\n\n<li><strong>Xolair<\/strong> (allergy &amp; asthma)<\/li>\n\n\n\n<li><strong>Hemlibra<\/strong> (hemophilia)<\/li>\n\n\n\n<li><strong>Ocrevus<\/strong> (multiple sclerosis)<\/li>\n\n\n\n<li><strong>Polivy<\/strong> (lymphoma ADC)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-adjustments-6-nmes-terminated-in-q3-2025\"><strong>Pipeline Adjustments \u2013 6 NMEs Terminated in Q3\u202f2025<\/strong><\/h3>\n\n\n\n<p>Roche\u2019s investor presentation disclosed the removal of six new molecular entities (NMEs) from its pipeline:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Molecule (assumed)<\/th><th>Target<\/th><th>Development Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>SOF10 (anti\u2011TGF\u2011\u03b21)<\/td><td>Solid tumors<\/td><td>Chugai<\/td><\/tr><tr><td><\/td><td>STA551 (CD137 switch antibody)<\/td><td>Solid tumors<\/td><td>Chugai<\/td><\/tr><tr><td><\/td><td>Paralutide (RAS inhibitor)<\/td><td>Solid tumors<\/td><td>Chugai<\/td><\/tr><tr><td><\/td><td>SAIL66 (anti\u2011CLDN6 trispecific)<\/td><td>CLDN6+ solid tumors<\/td><td>Chugai<\/td><\/tr><tr><td><\/td><td>RG6436 (LepB inhibitor)<\/td><td>Urinary tract infection<\/td><td>Genentech<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>AMY109 (anti\u2011IL8 antibody)<\/td><td>Endometriosis<\/td><td>Chugai<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>All five Chugai\u2011led projects were discontinued at the Phase\u202fI stage, while the Genentech\u2011led RG6436 was also terminated. The decision reflects a strategic refocus on high\u2011potential assets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/251023_ir_q3.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 251023_ir_q3.\"><\/object><a id=\"wp-block-file--media-f81d2ff1-da06-4819-be62-2b0eb07c6169\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/251023_ir_q3.pdf\">251023_ir_q3<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/251023_ir_q3.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f81d2ff1-da06-4819-be62-2b0eb07c6169\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44191,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,940,163,939],"class_list":["post-44189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF\u202f45.86\u202fbillion (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to CHF\u202f35.56\u202fbillion (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching CHF\u202f10.3\u202fbillion (\u2248\u202fUSD\u202f12.9\u202fbillion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44189\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF\u202f45.86\u202fbillion (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to CHF\u202f35.56\u202fbillion (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching CHF\u202f10.3\u202fbillion (\u2248\u202fUSD\u202f12.9\u202fbillion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44189\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-23T11:32:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-23T11:32:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance\",\"datePublished\":\"2025-10-23T11:32:40+00:00\",\"dateModified\":\"2025-10-23T11:32:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2301.webp\",\"keywords\":[\"Finanical Reports\",\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44189#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44189\",\"name\":\"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2301.webp\",\"datePublished\":\"2025-10-23T11:32:40+00:00\",\"dateModified\":\"2025-10-23T11:32:41+00:00\",\"description\":\"Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF\u202f45.86\u202fbillion (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to CHF\u202f35.56\u202fbillion (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching CHF\u202f10.3\u202fbillion (\u2248\u202fUSD\u202f12.9\u202fbillion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44189\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44189#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance - Insight, China&#039;s Pharmaceutical Industry","description":"Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF\u202f45.86\u202fbillion (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to CHF\u202f35.56\u202fbillion (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching CHF\u202f10.3\u202fbillion (\u2248\u202fUSD\u202f12.9\u202fbillion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44189","og_locale":"en_US","og_type":"article","og_title":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance","og_description":"Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF\u202f45.86\u202fbillion (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to CHF\u202f35.56\u202fbillion (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching CHF\u202f10.3\u202fbillion (\u2248\u202fUSD\u202f12.9\u202fbillion).","og_url":"https:\/\/flcube.com\/?p=44189","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-23T11:32:40+00:00","article_modified_time":"2025-10-23T11:32:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44189#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44189"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance","datePublished":"2025-10-23T11:32:40+00:00","dateModified":"2025-10-23T11:32:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44189"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44189#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp","keywords":["Finanical Reports","OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44189#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44189","url":"https:\/\/flcube.com\/?p=44189","name":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44189#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44189#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp","datePublished":"2025-10-23T11:32:40+00:00","dateModified":"2025-10-23T11:32:41+00:00","description":"Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7\u202f% year\u2011on\u2011year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF\u202f45.86\u202fbillion (\u2248\u202fUSD\u202f57.6\u202fbillion), driven by a 9\u202f% rise in the Pharmaceuticals division to CHF\u202f35.56\u202fbillion (\u2248\u202fUSD\u202f44.66\u202fbillion). Diagnostics sales, however, posted only 1\u202f% growth, reaching CHF\u202f10.3\u202fbillion (\u2248\u202fUSD\u202f12.9\u202fbillion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44189#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44189"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44189#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp","width":1080,"height":608,"caption":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44189#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Reports 7\u202f% YoY Revenue Growth Through Q3\u202f2025, Raises Full\u2011Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44189"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44189\/revisions"}],"predecessor-version":[{"id":44192,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44189\/revisions\/44192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44191"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}